Home » Healthcare » Pharmaceuticals » Freezing of Gait Treatment Market

Freezing of Gait Treatment Market By Treatment Type (Oral Dopaminergic Medication, Wearable and Walking Aid Devices, Deep Brain Stimulation), By End User Segment (Hospitals, Clinics, Research and Academic Institutes) – Growth, Future Prospects, and Competitive Analysis, 2019 – 2027

Summary
Table Of Content

Freezing gait treatment market to exhibit productive growth during the forecast period.

The global freezing of gait treatment market is growing at a CAGR of 7.2%. Globally, the increasing prevalence of Parkinson’s disease has significantly increased the revenue of oral dopaminergic medications. In addition, FDA approval for new drugs and promising pipeline products in the equipment and devices segment in the Parkinson’s disease industry is driving the overall growth freezing of the gait treatment market globally.

Market Synopsis

Oral dopaminergic medication segment is expected to register higher growth by the end of 2027

Levodopa (Inbrija™, by Acorda Therapeutics) and carbidopa remain the optimum standard of symptomatic treatment for (FoG) Parkinson’s disease orally. In Dec 2018, the U.S. FDA approved Inbrija™ for the alternating treatment of “OFF” incidents in people with Parkinson’s disease who are already treated with levodopa/carbidopa. It is a novel approach for the treatment of OFF periods in PD. Advanced pipeline products in the wearable and walking aid segment will show promising growth in the near future. E.g., At the CES 2018 conference in Las Vegas, a Chinese company named GYENNO showcased its gait aid equipment package, which mainly helps to escape gait freeze in Parkinson’s patients. Additionally, Kyungpook National University showcased an android-based gait-aid system using smart glasses with wearable sensors.

Access crucial information at unmatched prices!

Request your free sample report today & start making informed decisions powered by Credence Research!

Download Free Sample

Increasing admissions for freezing of gait in the hospital segment to witness a significant CAGR

Increasing chronic Parkinson’s disease (PD), along with significant hospital admissions internationally, are notable factors expected for the market’s growth. According to FDA and other research studies, symptomatic and neuroprotective therapies are opted for PD in hospitals. In addition, deep brain stimulation procedures, along with helpful brain exercises, are also adopted in the end-user segment, showed promising results in recent times. Moreover, the increasing elderly population and admissions are escalating the growth in the end-user segment. Moreover, the lunch of new medications and equipment in the U.S. market and internationally, along with increased funding for PD patient care for the administration of freezing of gait treatment on a global scale, will drive the growth during the forecast period.

Increasing population, new FDA approval, and the presence of top players hold the U.S. in a dominant position

In 2018, the U.S contributed the maximum revenue share in the freezing of the gait treatment market due to the rising prevalence of PD. Key prime factors include rising awareness about new medications and therapies, FDA approvals for new drugs, and rising PD care services along with enhanced reimbursement structure will drive the demand in the near future. In addition, emerging nations always suffer the burden of chronic diseases. Nevertheless, there is no significant treatment targeted towards freezing of gait in PD, but strong pipeline drugs and products, along with the approval for levodopa, will further enhance the growth on a global scale.

Increased research and development with strong product pipelines in the developed regions

Major players in the freezing of gait treatment market are Acorda Therapeutics, The Michael J. Fox Foundation, GYENNO, National University of Ireland, Galway (NUI Galway), Kyungpook National University, Republic of Korea, MedEXO Robotics, TABLE Teva Pharmaceuticals, and others. In addition, major organizations and research centers are developing progressive technologies with new technology expansion in the wearable and walking aids systems, electronic brain implants, and other stimulators for freezing gait treatment on a global scale.

Historical & Forecast Period

This study report represents an analysis of each segment from 2017 to 2027, considering 2018 to be the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period from 2019 to 2027.

Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!

Customize Now

Segmentation Treatment Type (2017–2027; US$ Mn)

Oral Dopaminergic Medication (Inbrija – levodopa inhalation powder)
Wearable and Walking Aid Devices
Deep Brain Stimulation
Others (Brain Implants)

End-User Segment (2017–2027; US$ Mn)

Hospitals
Clinics
Research and Academic Institutes

Geography Segment (2017–2027; US$ Mn)

North America (U.S., Canada)
Europe (U.K., Germany, Rest of Europe)
Asia Pacific (Japan, China, Rest of Asia Pacific)
Latin America (Brazil, Mexico, Rest of Latin America)
Middle East & Africa (GCC, Rest of the Middle East & Africa)

The current report also comprehends qualitative and qualitative market valuation factors such as key market drivers, market trends, restraints, and opportunities that give a better market understanding of the overall freezing of the gait treatment market. The global report also comprises a graphical representation of the competitive landscape based on their market initiatives and strategies, product portfolio, and business strengths.

Chapter 1. Preface
1.1. Report Description
1.1.1. Study Purpose
1.1.2. Target Audience
1.1.3. USP and Key Offerings
1.2. Market Segmentation
1.3. Research Scope
1.4. Research Methodology
1.4.1. Phase I – Secondary Research
1.4.2. Phase II – Primary Research
1.4.3. Phase III – Expert Panel Review
1.4.4. Assumptions
1.5. Market Segmentation

Chapter 2. Executive Summary
2.1. Global FGT Market Portraiture
2.2. Global FGT Market, By Treatment Type, 2018 (US$ Mn)
2.3. Global FGT Market, By End User, 2018 (US$ Mn)
2.4. Global FGT Market, by Geography, 2018 vs. 2027 (Value %)

Chapter 3. Global Freezing of Gait Treatment (FGT) Market: Market Dynamics and Future Outlook
3.1. Market Overview
3.2. FGT Market Technologies: Future Trends
3.3. Current Scenario: New Product Launches, High Prevalence For Parkinson’s Disease
3.4. Challenges
3.5. Opportunities
3.6. Attractive Investment Proposition, by Geography, 2018
3.7. Competitive Landscape
3.7.1. Competitive Landscape, by Key Players, 2018

Chapter 4. Global Freezing of Gait Treatment (FGT) Market, by Treatment Type, 2017 – 2027 (US$ Mn)
4.1. Overview
4.2. Oral Dopaminergic Medication (Inbrija – levodopa inhalation powder)
4.3. Wearable and Walking Aid Devices
4.4. Deep Brain Stimulation
4.5. Others (Brain Implants)

Chapter 5. Global Freezing of Gait Treatment (FGT) Market, By End User, 2017 – 2027 (US$)
5.1. Overview
5.2. Hospitals
5.3. Clinics
5.4. Research and Academic Institutes

Chapter 6. Global Freezing of Gait Treatment (FGT) Market, by Geography, 2017 – 2027 (US$ Mn)
6.1. Overview
6.2. North America FGT Market Analysis, 2017 – 2027
6.2.1. North America FGT Market, By Treatment Type, 2017 – 2027 (US$ Mn)
6.2.2. North America FGT Market, By End User, 2017 – 2027 (US$ Mn)
6.2.3. North America FGT Market, by Country, 2017 – 2027 (US$ Mn)
6.2.3.1. U.S.
6.2.3.2. Canada
6.3. Europe FGT Market Analysis, 2017 – 2027
6.3.1. Europe FGT Market, By Treatment Type, 2017 – 2027 (US$ Mn)
6.3.2. Europe FGT Market, By End User, 2017 – 2027 (US$ Mn)
6.3.3. Europe FGT Market, by Country, 2017 – 2027 (US$ Mn)
6.3.3.1. U.K.
6.3.3.2. Germany
6.3.3.3. Rest of Europe
6.4. Asia Pacific FGT Market Analysis, 2017 – 2027
6.4.1. Asia Pacific FGT Market, By Treatment Type, 2017 – 2027 (US$ Mn)
6.4.2. Asia Pacific FGT Market, By End User, 2017 – 2027 (US$ Mn)
6.4.3. Asia Pacific FGT Market, by Country, 2017 – 2027 (US$ Mn)
6.4.3.1. Japan
6.4.3.2. China
6.4.3.3. Rest of APAC
6.5. Latin America FGT Market Analysis, 2017 – 2027
6.5.1. Latin America FGT Market, By Treatment Type, 2017 – 2027 (US$ Mn)
6.5.2. Latin America FGT Market, By End User, 2017 – 2027 (US$ Mn)
6.5.3. Latin America FGT Market, by Country, 2017 – 2027 (US$ Mn)
6.5.3.1. Brazil
6.5.3.2. Mexico
6.5.3.3. Rest of Latin America
6.6. Middle East & Africa (MEA) FGT Market Analysis, 2017 – 2027
6.6.1. MEA FGT Market, by Treatment Type, 2017 – 2027 (US$ Mn)
6.6.2. MEA FGT Market, By End User, 2017 – 2027 (US$ Mn)
6.6.3. MEA FGT Market, by Region, 2017 – 2027 (US$ Mn)
6.6.3.1. GCC
6.6.3.2. Rest of MEA

Chapter 7. Company Profiles
7.1. Acorda Therapeutics
7.1.1. Business Description
7.1.2. Financial Information (Subject to data availability)
7.1.3. Product Portfolio
7.1.4. Key Developments
7.2. The Michael J. Fox Foundation
7.3. GYENNO
7.4. National University of Ireland, Galway (NUI Galway)
7.5. Kyungpook National University, Republic of Korea
7.6. MedEXO Robotics

List of Figures

FIG. 1 Global Freezing of Gait Treatment (FGT) Market: Research Methodology
FIG. 2 Market Size Estimation – Top Down & Bottom up Approach
FIG. 3 Global FGT Market Segmentation
FIG. 4 Global FGT Market, by Treatment Type, 2017 (US$ Mn)
FIG. 5 Global FGT Market, by End User, 2017 (US$ Mn)
FIG. 6 Global FGT Market, by Geography, 2017 (US$ Mn)
FIG. 7 Attractive Investment Proposition, by Geography, 2017
FIG. 8 Global Market Positioning of Key FGT Market Manufacturers, 2017
FIG. 9 Global FGT Market for Oral Dopaminergic Medication, 2017–2027 (US$ Mn)
FIG. 10 Global FGT Market for Wearable and Walking Aid Devices, 2017–2027 (US$ Mn)
FIG. 11 Global FGT Market for Deep Brain Stimulation, 2017–2027 (US$ Mn)
FIG. 12 Global FGT Market for Others (Brain Implants), 2017–2027 (US$ Mn)
FIG. 13 Global Hospitals Market (End User), 2017–2027 (US$ Mn)
FIG. 14 Global Clinics Market (End User), 2017–2027 (US$ Mn
FIG. 15 Global Research and Academic Institutes Market (End User), 2017–2027 (US$ Mn
FIG. 16 U.S. FGT Market, 2017–2027 (US$ Mn)
FIG. 17 Canada FGT Market, 2017–2027 (US$ Mn)
FIG. 18 U.K. FGT Market, 2017–2027 (US$ Mn)
FIG. 19 Germany FGT Market, 2017–2027 (US$ Mn)
FIG. 20 Rest of Europe FGT Market, 2017–2027 (US$ Mn)
FIG. 21 Japan FGT Market, 2017–2027 (US$ Mn)
FIG. 22 China FGT Market, 2017–2027 (US$ Mn)
FIG. 23 Rest of Asia Pacific FGT Market, 2017–2027 (US$ Mn)
FIG. 24 Brazil FGT Market, 2017–2027 (US$ Mn)
FIG. 25 Mexico FGT Market, 2017–2027 (US$ Mn)
FIG. 26 Rest of Latin America FGT Market, 2017–2027 (US$ Mn)
FIG. 27 GCC FGT Market, 2017–2027 (US$ Mn)
FIG. 28 Rest of Middle East & Africa FGT Market, 2017–2027 (US$ Mn)

List of Tables

TABLE 1 Market Snapshot: Global Freezing of Gait Treatment (FGT) Market
TABLE 2 Global FGT Market, by Treatment Type, 2017–2027 (US$ Mn)
TABLE 3 Global FGT Market, by End User, 2017–2027 (US$ Mn)
TABLE 4 Global FGT Market, by Geography, 2017–2027 (US$ Mn)
TABLE 5 North America FGT Market, by Treatment Type, 2017–2027 (US$ Mn)
TABLE 6 North America FGT Market, by End User, 2017–2027 (US$ Mn)
TABLE 7 North America FGT Market, by Country, 2017–2027 (US$ Mn)
TABLE 8 Europe FGT Market, by Treatment Type, 2017–2027 (US$ Mn)
TABLE 9 Europe FGT Market, by End User, 2017–2027 (US$ Mn)
TABLE 10 Europe FGT Market, by Country/Region, 2017–2027 (US$ Mn)
TABLE 11 Latin America FGT Market, by Treatment Type, 2017–2027 (US$ Mn)
TABLE 12 Latin America FGT Market, by End User, 2017–2027 (US$ Mn)
TABLE 13 Latin America FGT Market, by Country/Region, 2017–2027 (US$ Mn)
TABLE 14 Asia Pacific FGT Market, by Treatment Type, 2017–2027 (US$ Mn)
TABLE 15 Asia Pacific FGT Market, by End User, 2017–2027 (US$ Mn)
TABLE 16 Asia Pacific FGT Market, by Country/Region, 2017–2027 (US$ Mn)
TABLE 17 Middle East & Africa FGT Market, by Treatment Type, 2017–2027 (US$ Mn)
TABLE 18 Middle East & Africa FGT Market, by End User, 2017–2027 (US$ Mn)
TABLE 19 Middle East & Africa FGT Market, by Region, 2017–2027 (US$ Mn)
TABLE 20 Acorda Therapeutics.: Company Snapshot (Company Overview; Product Portfolio; Financial Information; Key Developments)
TABLE 21 The Michael J. Fox Foundation.: Company Snapshot (Company Overview; Product Portfolio; Financial Information; Key Developments)
TABLE 22 GYENNO..: Company Snapshot (Company Overview; Product Portfolio; Financial Information; Key Developments)
TABLE 23 National University of Ireland, Galway (NUI Galway): Company Snapshot (Company Overview; Product Portfolio; Financial Information; Key Developments)
TABLE 24 Kyungpook National University, Republic of Kore: Company Snapshot (Company Overview; Product Portfolio; Financial Information; Key Developments)
TABLE 25 MedEXO Robotics: Company Snapshot (Company Overview; Product Portfolio; Financial Information; Key Developments)
TABLE 26 Teva Pharmaceuticals: Company Snapshot (Company Overview; Product Portfolio; Financial Information; Key Developments)

Frequently Asked Questions

What is the size of Freezing of Gait Treatment Market?

The market for Freezing of Gait Treatment Market is expected to reach US$ XX Bn by 2027.

What is the Freezing of Gait Treatment Market CAGR?

The Freezing of Gait Treatment Market is expected to see significant CAGR growth over the coming years, at 7.2%.

What is the Forecast period considered for Freezing of Gait Treatment Market?

The report is forecasted from 2018-2027.

What is the base year considered for Freezing of Gait Treatment Market?

The base year of this report is 2017.

Who are the major players in this market?

Acorda Therapeutics, The Michael J. Fox Foundation, GYENNO, National University of Ireland, Galway (NUI Galway), Kyungpook National University, Republic of Korea, MedEXO Robotics are some of the major players in the global market.

Purchase Options

Request Free Sample

Have a question?

Don’t settle for less – trust Mitul to help you find the best solution.

Call: +91 6232 49 3207

EMAIL MITUL

Report delivery within 24 to 48 hours

– Other Info –

–What people say?-

I am very impressed with the information in this report. The author clearly did their research when they came up with this product and it has already given me a lot of ideas.

Jana Schmidt
CEDAR CX Technologies

– Connect with us –